TerminatedPHASE1, PHASE2NCT02584647
PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors
Studying Fibrosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gulam Manji
- Principal Investigator
- Gulam A. Manji, MDColumbia University
- Intervention
- PLX3397(drug)
- Enrollment
- 39 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2024
Study locations (5)
- University of Iowa, Iowa City, Iowa, United States
- Early Drug Development Center, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Washington University in St. Louis, St Louis, Missouri, United States
- Columbia University, New York, New York, United States
Collaborators
Daiichi Sankyo
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02584647 on ClinicalTrials.govOther trials for Fibrosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT05566795DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)Day One Biopharmaceuticals, Inc.
- ACTIVE NOT RECRUITINGPHASE2NCT03834961Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute LeukemiaChildren's Oncology Group